Immune checkpoint blockade (ICB) therapy has evolved as a revolutionized therapeutic
modality to eradicate tumor cells by releasing the brake of the antitumor immune response …

Abstract Profiling the T-Cell Receptor (TCR) repertoire is establishing as a potent approach
to investigate autologous and treatment-induced antitumor immune response. Technical and …

Hepatocellular carcinoma (HCC) is one of the most fatal tumours worldwide and has a high
recurrence rate. Nevertheless, the mechanism of HCC genesis remains partly unexplored …

The importance of the tumor microenvironment (TME) in dynamically regulating cancer
progression and influencing the therapeutic outcome is widely accepted and appreciated …

Background The discovery of new anti-melanoma drugs with low side effect is urgently
required in the clinic. Recent studies showed that morusin, a flavonoid compound isolated …

Despite the significant progress in the treatment of unresectable or metastatic BRAF V600-
mutant melanoma, there remains two primary treatment options: targeted therapy and …

The foetus can be regarded as a half‐allograft implanted into the maternal body. In a
successful pregnancy, the mother does not reject the foetus because of the immune …

Simple Summary Cancer remains a major cause of morbidity and mortality for millions of
people across the globe. While immunotherapy using immune-checkpoint inhibitors (ICIs) is …

Simple Summary T cells have been considered, for a long time, key players in anti-cancer
responses triggered by treatment with immune checkpoint inhibitors, but our recent studies …

Background Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related
morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) including anti-PD-1 …